Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Resivant Medical
Akron, Ohio, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Resivant Medical has received FDA 510(k) clearance for its first two products, Cutiva Topical Skin Adhesive and Cutiva PLUS Skin Closure System. Preclinical animal studies showed performance comparable to leading devices (DERMABOND family) in wound closure efficacy, safety, and biocompatibility. Products are now cleared and available for clinical use.
- Therapeutic areas
- OtherDermatology
- Modalities
- Device
- Industry
- Surgical Medical Devices
Beyond the preview
Go deeper on Resivant Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Resivant Medical.